Gyre Therapeutics (GYRE) Asset Utilization Ratio (2011 - 2026)
Gyre Therapeutics (GYRE) reported Asset Utilization Ratio of 0.71 for Q1 2026, down 9.55% year-over-year from 0.79 in Q1 2025, and little changed on a QoQ basis from 0.72 in Q4 2025.
Gyre Therapeutics (GYRE) has 15 years of Asset Utilization Ratio data on file, last reported at 0.71 in Q1 2026.
- Quarterly Asset Utilization Ratio fell 9.55% year-over-year to 0.71 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.71 (down 9.55% YoY) and the FY2025 annual result came in at 0.8, down 8.51% from the prior year.
- Asset Utilization Ratio was little changed at 0.71 in Q1 2026 per GYRE's latest filing, from 0.72 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 16.8 in Q3 2023 and bottomed at 0.06 in Q3 2022.
- The 5-year median for Asset Utilization Ratio is 0.84 (2024), against an average of 2.37.
- The widest annual swing landed in 2023, when Asset Utilization Ratio surged 29610.75%; it then slumped 94.92% in 2024.
- Tracing GYRE's Asset Utilization Ratio over 5 years: stood at 1.77 in 2022, then grew by 1.5% to 1.79 in 2023, then plunged by 52.95% to 0.84 in 2024, then fell by 15.11% to 0.72 in 2025, then decreased by 0.41% to 0.71 in 2026.
- Per Business Quant, the three latest GYRE Asset Utilization Ratio figures stand at 0.71 (Q1 2026), 0.72 (Q4 2025), and 0.69 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 0.71 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.71 |
| Dec 31, 2025 | 0.72 |
| Sep 30, 2025 | 0.69 |
| Jun 30, 2025 | 0.72 |
| Mar 31, 2025 | 0.79 |
| Dec 31, 2024 | 0.84 |
| Sep 30, 2024 | 0.85 |
| Jun 30, 2024 | 0.92 |
| Mar 31, 2024 | 0.97 |
| Dec 31, 2023 | 1.79 |
| Sep 30, 2023 | 16.80 |
| Jun 30, 2023 | 10.00 |
| Mar 31, 2023 | 2.44 |
| Dec 31, 2022 | 1.77 |
| Sep 30, 2022 | 0.06 |
| Jun 30, 2022 | 0.09 |
| Mar 31, 2022 | 0.14 |
| Dec 31, 2021 | 0.11 |
| Sep 30, 2021 | 0.08 |
| Jun 30, 2021 | 0.05 |
| Mar 31, 2021 | 0.06 |
| Dec 31, 2020 | 0.20 |
| Sep 30, 2020 | 0.16 |
| Jun 30, 2020 | 0.15 |
| Mar 31, 2020 | 0.16 |
| Dec 31, 2018 | 0.00 |
| Sep 30, 2018 | 0.00 |
| Jun 30, 2018 | 0.00 |
| Mar 31, 2018 | 0.01 |
| Dec 31, 2017 | 0.03 |
| Sep 30, 2017 | 0.02 |
| Jun 30, 2017 | 0.02 |
| Mar 31, 2017 | 0.02 |
| Dec 31, 2016 | 0.01 |
| Sep 30, 2016 | 0.01 |
| Jun 30, 2016 | 0.01 |
| Mar 31, 2016 | 0.02 |
| Dec 31, 2015 | 0.02 |
| Sep 30, 2015 | 0.03 |
| Jun 30, 2015 | 0.03 |
| Mar 31, 2015 | 0.04 |
| Dec 31, 2014 | 0.03 |
| Sep 30, 2014 | 0.01 |
| Jun 30, 2014 | 0.01 |
| Mar 31, 2014 | 0.00 |
| Dec 31, 2013 | 0.02 |
| Sep 30, 2013 | 0.03 |
| Jun 30, 2013 | 0.03 |
| Mar 31, 2013 | 0.21 |
| Dec 31, 2012 | 0.29 |
| Sep 30, 2012 | 0.37 |
| Jun 30, 2012 | 0.43 |
| Mar 31, 2012 | 0.33 |
| Dec 31, 2011 | 0.36 |
| Sep 30, 2011 | 0.35 |